Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | CLK1 | P49759 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984594 | 0.84 | LMNA (0.47) | IMPDH2LMNACYP3A4MAPTAPEX1 | |
| SCHEMBL22589259 | 0.76 | LMNA (0.42) | IMPDH2LMNACYP3A4MAPTAPEX1 | |
| SCHEMBL12266517 | 0.75 | LMNA (0.60) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL31401046 | 0.74 | IMPDH2 (0.50) | IMPDH2LMNACYP3A4KDM4ECYP1A2 | |
| SCHEMBL30692011 | 0.74 | F12 (0.57) | IMPDH2LMNACYP3A4MAPTKDM4E | |
| SCHEMBL246633 | 0.74 | F12 (0.57) | IMPDH2LMNACYP3A4MAPTKDM4E | |
| SCHEMBL3386889 | 0.74 | IMPDH2 (0.50) | IMPDH2LMNACYP3A4KDM4ECYP1A2 | |
| SCHEMBL2012410 | 0.74 | KDM4E (0.44) | IMPDH2LMNACYP3A4KDM4ECYP1A2 | |
| SCHEMBL277425 | 0.74 | KDM4E (0.53) | IMPDH2LMNACYP3A4MAPTKDM4E | |
| SCHEMBL18544875 | 0.74 | HTT (0.44) | IMPDH2LMNACYP3A4KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| EP-3959214-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| EP-3759106-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Karus Therapeutics Ltd (GB) | 2021-01-06 | — | — | EP | disclosed |
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | disclosed |
| WO-2002068393-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002057242-A2 | UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002053558-A1 | QUINAZOLONE DERIVATIVES AS ALPHA 1A/B ADRENERGIC RECEPTOR ANTAGONISTS | F.HOFFMAN-LA ROCHE AG (CH) | 2002-07-11 | — | — | WO | disclosed |
| US-20020072607-A1 | Inhibit binding of integrins to their ligands and are of use in prophylaxis and therapy of of immune or inflammatory disorders, or disorders including inappropriate growth or migration of cells | CELLTECH R&D, LTD. (GB) | 2002-06-13 | — | — | US | disclosed |
| US-20020037909-A1 | Enamine derivatives | UCB PHARMA S.A. (BE) | 2002-03-28 | — | — | US | disclosed |
| WO-2002020522-A1 | BICYCLIC ENAMIDE DERIVATIVES BEING INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
| EP-1181266-A1 | SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001079173-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R & D LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
| WO-2000073260-A1 | SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R&D LIMITED (GB) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037909-A1 | Enamine derivatives | CCR1, ITGB2, CCR10 | IMPDH2 4513/4885LMNA 2974/4885CYP3A4 1265/4885 |
| US-20020072607-A1 | Inhibit binding of integrins to their ligands and are of use in prophylaxis and therapy of of immune or inflammatory disorders, or disorders including inappropriate growth or migration of cells | ITGB2, VCAM1, ITGB1 | IMPDH2 4529/4885LMNA 2667/4885CYP3A4 3001/4885 |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC3 | IMPDH2 3951/4885LMNA 3656/4885CYP3A4 1550/4885 |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | BMI1, EZH2, SUZ12 | IMPDH2 3580/4885LMNA 3312/4885CYP3A4 3711/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | IMPDH2 3782/4885LMNA 1281/4885CYP3A4 4381/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | IMPDH2 3885/4885LMNA 2546/4885CYP3A4 2065/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | IMPDH2 3580/4885LMNA 3312/4885CYP3A4 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.